Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
45.47
-0.29 (-0.63%)
Nov 21, 2024, 1:21 PM EST - Market open

Halozyme Therapeutics Revenue

Halozyme Therapeutics had revenue of $290.08M in the quarter ending September 30, 2024, with 34.28% growth. This brings the company's revenue in the last twelve months to $947.36M, up 21.35% year-over-year. In the year 2023, Halozyme Therapeutics had annual revenue of $829.25M with 25.62% growth.

Revenue (ttm)
$947.36M
Revenue Growth
+21.35%
P/S Ratio
6.16
Revenue / Employee
$2,539,826
Employees
373
Market Cap
5.79B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023829.25M169.14M25.62%
Dec 31, 2022660.12M216.81M48.91%
Dec 31, 2021443.31M175.72M65.67%
Dec 31, 2020267.59M71.60M36.53%
Dec 31, 2019195.99M44.13M29.06%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
R1 RCM 2.46B
RadNet 1.77B
Lantheus Holdings 1.50B
Waystar Holding 906.14M
Ionis Pharmaceuticals 803.07M
Inspire Medical Systems 755.59M
Corcept Therapeutics 628.56M
Blueprint Medicines 434.42M
Revenue Rankings